NCT02749903 · OUTCOME

Number of Patients Experiencing at Least One Grade 3+ Adverse Event Using CTCAE Version 4.0

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers · Source last updated 2026-10-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 30 days post-treatment, up to 32 months

What was measured

The number of patients experiencing at least one grade 3+ adverse event using CTCAE version 4.0 is summarized below.

Groups in this outcome

Enzalutamide

Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Enzalutamide	46

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide	22	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
22

denoms

counts
group Id
OG000
value
46
units
Participants

description

The number of patients experiencing at least one grade 3+ adverse event using CTCAE version 4.0 is summarized below.

groups

description
Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
id
OG000
title
Enzalutamide

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

30 days post-treatment, up to 32 months

title

Number of Patients Experiencing at Least One Grade 3+ Adverse Event Using CTCAE Version 4.0

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice